Sotio

Sotio a.s. [1] is a biotechnology company belonging to the PPF Group owned by Petr Kellner. Since March 2014, the head of the company is Ladislav Bartoníček,[2] the former head of Česká pojišťovna (Czech Insurance Company). The company focuses on research and development of medicines for cancer and autoimmune diseases.[3] Besides European countries, it also operate in the USA, Russia and China.[1] In 2014, the Sotio company opened a laboratory complex in China where it produce drugs for people suffering from oncological diseases.[4] Similar laboratories opened in Prague in 2011 already.

The company became well known for developing drugs for prostate cancer, ovarian cancer [5] and lung cancer.[3][6]

References

  1. 1 2 "The company - About us - Sotio a.s.". sotio.com.
  2. ↑ "Kellnerovo biotechnologické Sotio povede exšéf České pojišťovny Bartoníček". Hospodářské noviny.
  3. 1 2 "Kellnerova firma Sotio zahájila testy léku na rakovinu plic". E15.cz.
  4. ↑ "Firma Sotio otevřela v Číně laboratoř, má pomoci proti rakovině". mednes.cz.
  5. ↑ "Kellnerova firma začala test léku na rakovinu vaječníků". Aktuálně.cz - Víte co se právě děje.
  6. ↑ Zuzana Kubátová (6 January 2015). "Kellnerova firma začíná testovat už třetí lék, tentokrát na nádory plic". iDNES.cz.
This article is issued from Wikipedia - version of the 3/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.